Clinical Trials
Clinical Trial Detail
Return to search results.
Study of MDX-1105 in Subjects With Selected Advanced or Recurrent Solid Tumors (MDX1105-01)
Complete title: A Phase 1, Open label, Multicenter, Dose escalation, Multidose Study of BMS 936559 (MDX 1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors (WIRB's Study#: 1107927, Protocol#: 20082100)
| Research Study Number | 7104 | ||
| Principal Investigator | Scott Tykodi, MD | ||
| Phase | I |
Research Study Description
The primary purpose of this study is to determine if MDX-1105 is safe and tolerated when administered every 14 days to subjects with selected advanced or recurrent solid tumors.
Eligibility Criteria (must meet the following to participate in this study)
Genders Eligible for Study: Both
- ECOG PS 0 to 2
- Relapsed/refractory renal cell carcinoma, NSCLC, malignant melanoma, epithelial ovarian cancer, colorectal adenocarcinoma
- Must have measurable disease
Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
- No prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody
- No active infection (viral, bacterial or fungal)
- No active autoimmune disease or a documented history of autoimmune disease or history of syndrome that requires systemic steroids or immunosuppressive medications.
- No active or latent infection
Other exclusion criteria may apply.
|
Keywords
Colon Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Gynecological Cancer; Kidney Cancer; Lung Cancer; Melanoma; Ovarian Cancer; Renal Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
- Diseases
& Research
- Treatment
& Support
- About Us
- Labs &
Projects
- Events &
Community Programs
- How You
Can Help Us
The Hutchinson Center's world-renowned scientists are discovering new ways to detect, prevent and treat cancer, HIV/AIDS and many other diseases.
- License Our Discoveries
The Hutchinson Center's world-renowned researchers work together to pursue lifesaving therapies that will help eliminate cancer and related diseases.
The Hutchinson Center's clinical research breakthroughs are delivered to patients through our treatment arm, the Seattle Cancer Care Alliance. This collaboration combines the strengths of the Hutchinson Center, UW Medicine and Seattle Children's.
You can help eliminate cancer and related diseases by attending Hutchinson Center events and participating in our other fundraising and community efforts.
- Divisions
The Hutchinson Center's pioneering researchers push the boundaries of science to find new ways to prevent, detect and treat cancer and related diseases.
Private support is critical to fund new research ideas and innovations, accelerating our ability to make lifesaving discoveries.
